Business
Qilian International Holding Group Limited Receives Approval for the Sale of its Newly Developed Nitrofurantoin Enteric-coated Tablets
JIUQUAN, China, Jan. 19, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or
About this update from Bgm Group Ltd.
[{"type":"text","content":"JIUQUAN, China, Jan. 19, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the \"Company\", \"Qilian International\", \"we\", \"our\" or \"us\"), a China-based pharmaceutical and chemical products manufacturer, today announced that the Company received approval from Gansu Provincial Drug Administration on January 14, 2022 for the sale of its newly developed nitrofurantoin enteric-coated tablets. This indicates that the Company officially become the first enterprise in Gansu Province with the Gansu Provincial Drug Administration's approval for selling nitrofurantoin enteric-coated tablets.\nIncluded as a class-A medicine in the National Reimbursement Drug List and the National Essential Medicines List in China, nitrofurantoin enteric-coated tablets are expected to have a robust market demand with large growth potential. Nitrofurantoin enteric-coated tablets are mainly used for the treatment of acute lower urinary tract infections caused by bacteria such as Escherichia coli, Enterococcus, Staphylococcus, Klebsiella, and Enterobacter. Nitrofurantoin enteric-coated tablets also can be used to prevent urinary tract infections and are commonly used as anti-inflammatory and bactericidal drugs.\nThe Company's nitrofurantoin enteric-coated tablets have successfully passed the on-site inspection and comprehensive evaluation by the Examination and Inspection Center of the Gansu Provincial Drug Administration. The Examination and Inspection Center of the Gansu Provincial Drug Administration determined that the Company's production process for the nitrofurantoin enteric-coated tablets is consistent with the approved registration process, its production and quality management of nitrofurantoin enteric-coated tablets meet the requirements of Good Manufacturing Practice, and its production facilities and quality control system meet the needs of the production scale. Qilian International's nitrofurantoin enteric-coated tablets have been sampled by Examination and Inspection Center of the Gansu Provincial Drug Administration and tested by Gansu Provincial Institute of Drug Inspection. As a result of the foregoing approvals, the Company's nitrofurantoin enteric-coated tablets have been determined by the applicable authorities to meet the national drug standards.\nMr. Zhanchang Xin, Chairman and CEO of the Company, comm...